AstraZeneca's Oncology Business
GPTKB entity
Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Association
|
| gptkbp:aimsTo |
Personalized Medicine
Improve_Patient_Outcomes |
| gptkbp:collaboratesWith |
Research Institutions
|
| gptkbp:competesWith |
gptkb:Merck
gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Roche |
| gptkbp:contributedTo |
Market Share
Revenue Growth Innovation in Oncology |
| gptkbp:develops |
Oncology Drugs
|
| gptkbp:engagesIn |
Clinical Trials
|
| gptkbp:focusesOn |
Cancer Treatment
|
| gptkbp:hasCollaborationsWith |
Academic Institutions
Biotech_Companies Healthcare_Providers |
| gptkbp:hasPart |
Regulatory Affairs Team
Medical Affairs Team Commercial Team Oncology Pipeline Market_Access_Team |
| gptkbp:hasProductLine |
gptkb:Lynparza
gptkb:Zoladex Imfinzi Tagrisso Calquence |
| gptkbp:headquarteredIn |
gptkb:Cambridge,_UK
|
| https://www.w3.org/2000/01/rdf-schema#label |
AstraZeneca's Oncology Business
|
| gptkbp:investmentFocus |
Research_and_Development
|
| gptkbp:isInvolvedIn |
Health Economics
Patient Advocacy Real-World Evidence |
| gptkbp:isPartOf |
AstraZeneca's_Corporate_Strategy
|
| gptkbp:isRecognizedFor |
Innovative Therapies
Clinical Excellence Patient-Centric_Approach |
| gptkbp:isSupportedBy |
Artificial Intelligence
Global Oncology Strategy Data_Analytics Digital_Health_Initiatives |
| gptkbp:operatesIn |
Global_Markets
|
| gptkbp:partOf |
gptkb:AstraZeneca
|
| gptkbp:targets |
Solid Tumors
Hematological Malignancies |
| gptkbp:utilizes |
Biomarkers
Genomic Profiling |